Antianginal and anti-ischaemic efficacy of tedisamil, a potassium channel blocker

Heart

Volumn 83, Issue 2, 2000, Pages 167-171

  Fox, K M ^a   Henderson, J R ^a   Kaski, J C ^b   Sachse, A ^c   Kuester, L ^c   Wonnacott, S ^d  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c Solvay Pharmaceuticals GmbH   (Germany)

^d Solvay Healthcare Ltd   (United Kingdom)

Author keywords

Potassium channel blocker; Stable angina; Tedisamil

Indexed keywords

NITRATE; PLACEBO; POTASSIUM CHANNEL BLOCKING AGENT; TEDISAMIL;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG UTILIZATION; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT DEPRESSION; TREADMILL EXERCISE; TREATMENT OUTCOME;

EID: 0034124311     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.83.2.167     Document Type: Article

References (5)

1. + currents in mammalian cardiac anglial cells. J Pharmacol Exp Ther 1990;254:560-9.
2. + channels. Cardiovasc Drugs Ther 1992;6:321-7.
3. 3 Mitrovic V, Oehm E, Liebrich A, et al. Haemodynamic and anti-ischaemic effects of tedisamil in humans. Cardiovasc Drugs Ther 1992:6:353-60.
4. 4 Burgheer K, Bode F, Klein V, et al. Prolongation of monophasic action potential duration and the refractory period in the human heart by tedisamil, a new potassium blocking agent. Eur Heart J 1994;15:1409-14.
5. 5 Demolis J-L, Martel C, Funck-Brentano C, et al. Effects of tedisamil, atenolol and their combination on heart and rate-dependent QT interval in healthy volunteers. Br J Clin Pharmacol 1997;44:403-9.